CTLA4 and colorectal adenocarcinoma: In our study, risk score was significantly negatively correlated with CTLA4, PDL1, and PDL2, indicating that female advanced colorectal adenocarcinoma patients with lower risk scores are more likely to benefit from immunotherapy of anti-CTLA4, anti-PDL1, and anti-PDL2.